New & Notable
GLP-1 drugs show promise in managing chronic migraines
Chronic migraine patients taking GLP-1s are associated with fewer ER visits, hospitalizations and treatment interventions than those taking a common first-line migraine drug, a study shows.
Boehringer Ingelheim adds 3 drugs to TrumpRx
Boehringer Ingelheim is the latest drugmaker to make good on its TrumpRx deal with the White House, expanding the self-pay platform's offerings by three more medications.
Novo uses FDA voucher to win speedy approval of higher-dose Wegovy
The clearance, issued 54 days after an approval submission, gives Novo another chance to claw back market share from Eli Lilly.
— BioPharma Dive
Lilly's triple-G agonist shows unique promise in late-stage diabetes trial
Eli Lilly's experimental triple hormone agonist, retatrutide, helped patients with type 2 diabetes lower blood sugar by up to 2% and lose up to 16.8% of their weight in a phase 3 study.
Federal court blocks RFK Jr.’s moves to upend US vaccine policy
— BioPharma DiveHealthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
Regeneron's GLP-1/GIP obesity drug succeeds in late-stage trial
Regeneron's dual GLP-1/GIP obesity shot, licensed from Hansoh Pharma, achieved phase 3 weight-loss results that come close to those of Lilly's Zepbound, but with better GI tolerability.
-
Roche, Zealand tout the tolerability of their amylin obesity drug
The Roche–Zealand amylin obesity drug, petrelintide, delivered up to 10.7% weight loss in a phase 2 obesity trial with a "placebo-like tolerability" profile, the companies say.
-
Lilly rolls out Employer Connect to close obesity coverage gaps
Eli Lilly debuts Employer Connect, a direct-to-employer platform that helps companies make its GLP-1 obesity drug, Zepbound, more affordable and accessible for employees.
-
FDA continues crackdown on DTC advertising for compounded GLP-1s
Continuing its crackdown on direct-to-consumer advertising, the FDA has sent 30 more warning letters to companies making deceptive claims about their compounded GLP-1 products.
-
Lilly's GLP-1 diabetes pill beats Novo's Rybelsus in a head-to-head trial
Eli Lilly's GLP-1 pill, orforglipron, bested rival Novo Nordisk's Rybelsus in the first head-to-head late-phase diabetes trial but led to higher side effect rates.
-
Novo teams up with Vivtex to develop oral metabolic biologics
Novo Nordisk doubles down on oral drug delivery for the development of next-generation obesity and diabetes biologics, striking a licensing deal with Vivtex valued at up to $2.1 billion.
Features
-
5 emerging AI/ML trends in clinical research
Emerging AI and machine learning tools are reshaping clinical research as trial sponsors continue to grapple with rising costs, lengthy timelines and low success rates.
-
5 trends defining the next wave of life sciences M&A
As the market rebounds, five key trends are shaping the next wave of mergers and acquisitions in the life sciences industry.
-
GLP-1 drugs primed for FDA approval in 2026
With Pharma titans Eli Lilly and Novo Nordisk continuing to duke it out for control of the GLP-1 market, both are seeking FDA approval for new drugs this year.
-
Blurring the line between GLP-1 compounders, counterfeiters
Weak regulatory oversight has allowed 503A compounding facilities to abuse customization rules, blurring the line between GLP-1 compounders and unregulated drug manufacturers.